New production plant
Switzerland-based medical technology company Ypsomed is constructing a new production facility at the Schwerin industrial park in Germany.
The new facility will add to the company’s existing production sites in Switzerland, which are operating at full capacity. The existing facilities have already been expanded and have no scope for further capacity expansions beyond 2020.
The ground-breaking ceremony for the construction of the new facility took place in September 2017. Construction work is expected to be completed within 18 months, while operations are scheduled to commence in the first half of 2019.
Ypsomed is investing Sfr100m ($102.29m) in the project, with construction of the production facility estimated to cost €50m ($59.94m) and the production equipment estimated to cost another €50m ($59.94m).
The project will initially create 150 new jobs over five years, while additional jobs will be created as the production increases.
The new production facility is being developed in the Schwerin industrial park, which is located between Hamburg and Berlin. It features good infrastructure and is located in close proximity to the port of Hamburg, which provides shorter trading routes.
The industrial park provides facilities for multi-faceted industrial applications. It also offers advanced technologies ranging from primary production to successful distribution. The location also has an ample pool of qualified labour.
The new production facility is being developed on a 100,000m² site, which will include a production and administration building with a total floor space of 19,000m². It will also have an option to expand by another 100,000m² of area in the future.
A logistics warehouse, quality control and technical maintenance facilities will also be available.
The single-storey production space of the facility will include a clean room, storage facilities and tool store. It will also include a two-storey administrative area equipped with offices, meeting rooms and an auditorium.
The new facility will be equipped with plastic injection moulding equipment, printing facilities, and automated assembly and packaging equipment.
It will manufacture Ypsomed’s existing products, which are being produced at the company’s other sites in Switzerland. It will produce injection and infusion systems, and infusion sets for insulin pumps such as pens, auto-injectors and pump systems, which will be assembled, along with supplier parts to form finished end products.
The Schwerin facility will also enable Ypsomed to expand its UnoPen™ and the YpsoMate® autoinjector production capacities.
Specialist personnel who will work at the new facility will be trained in Switzerland.
Munich-based industrial design specialist IE Plast is responsible for the planning and realisation of the production facility. IE Plast’s contractual scope includes operation, building and qualification of the facility.
Ypsomed is a self-care medication solutions provider created following the split of Disetronic Group in 2003.
The co-founder and major stakeholder in Disetronic Holding sold the company, along with its infusion systems division to Roche in 2003. The injection systems division was, however, retained and eventually became an independent company named Ypsomed.
The products Ypsomed manufactures at its Switzerland facilities include ServoPen, UnoPen™, YpsoMate®, YpsoPen, FixPen, VerioJect, and LyoTwist.
Alnylam Pharmaceuticals is constructing a new drug substance manufacturing and cGMP warehouse facility in Norton, Massachusetts, US. The company broke…
Neopharma opened a pharmaceutical plant in Abu Dhabi, United Arab Emirates, in July 2003. The plant then entered a three-month…
French pharmaceutical company Sanofi’s manufacturing plant in Goa, India, is located in the Verna Industrial Park, owned by Sanofi’s Indian…
GlaxoSmithKline (GSK) began construction of an oral solid-dose manufacturing plant at the Vemgal Industrial Area in India in September 2015.…